180 related articles for article (PubMed ID: 7488245)
1. Induction of DT-diaphorase by doxorubicin and combination therapy with mitomycin C in vitro.
Begleiter A; Leith MK
Biochem Pharmacol; 1995 Oct; 50(8):1281-6. PubMed ID: 7488245
[TBL] [Abstract][Full Text] [Related]
2. Induction of DT-diaphorase by 1,2-dithiole-3-thiones in human tumour and normal cells and effect on anti-tumour activity of bioreductive agents.
Doherty GP; Leith MK; Wang X; Curphey TJ; Begleiter A
Br J Cancer; 1998 Apr; 77(8):1241-52. PubMed ID: 9579829
[TBL] [Abstract][Full Text] [Related]
3. Induction of DT-diaphorase in cancer chemoprevention and chemotherapy.
Begleiter A; Leith MK; Curphey TJ; Doherty GP
Oncol Res; 1997; 9(6-7):371-82. PubMed ID: 9406243
[TBL] [Abstract][Full Text] [Related]
4. Induction of DT-diaphorase by 1,2-dithiole-3-thione and increase of antitumour activity of bioreductive agents.
Begleiter A; Leith MK; Curphey TJ
Br J Cancer Suppl; 1996 Jul; 27():S9-14. PubMed ID: 8763837
[TBL] [Abstract][Full Text] [Related]
5. Enhanced cytotoxicity of mitomycin C in human tumour cells with inducers of DT-diaphorase.
Wang X; Doherty GP; Leith MK; Curphey TJ; Begleiter A
Br J Cancer; 1999 Jun; 80(8):1223-30. PubMed ID: 10376975
[TBL] [Abstract][Full Text] [Related]
6. The effect of functional groups on reduction and activation of quinone bioreductive agents by DT-diaphorase.
Fourie J; Oleschuk CJ; Guziec F; Guziec L; Fiterman DJ; Monterrosa C; Begleiter A
Cancer Chemother Pharmacol; 2002 Feb; 49(2):101-10. PubMed ID: 11862423
[TBL] [Abstract][Full Text] [Related]
7. Reductase enzyme expression across the National Cancer Institute Tumor cell line panel: correlation with sensitivity to mitomycin C and EO9.
Fitzsimmons SA; Workman P; Grever M; Paull K; Camalier R; Lewis AD
J Natl Cancer Inst; 1996 Mar; 88(5):259-69. PubMed ID: 8614004
[TBL] [Abstract][Full Text] [Related]
8. Establishment of an isogenic human colon tumor model for NQO1 gene expression: application to investigate the role of DT-diaphorase in bioreductive drug activation in vitro and in vivo.
Sharp SY; Kelland LR; Valenti MR; Brunton LA; Hobbs S; Workman P
Mol Pharmacol; 2000 Nov; 58(5):1146-55. PubMed ID: 11040064
[TBL] [Abstract][Full Text] [Related]
9. The importance of DT-diaphorase in mitomycin C resistance in human colon cancer cell lines.
Lambert PA; Kang Y; Greaves B; Perry RR
J Surg Res; 1998 Dec; 80(2):177-81. PubMed ID: 9878310
[TBL] [Abstract][Full Text] [Related]
10. Over-expression of DT-diaphorase in transfected NIH 3T3 cells does not lead to increased anticancer quinone drug sensitivity: a questionable role for the enzyme as a target for bioreductively activated anticancer drugs.
Powis G; Gasdaska PY; Gallegos A; Sherrill K; Goodman D
Anticancer Res; 1995; 15(4):1141-5. PubMed ID: 7653992
[TBL] [Abstract][Full Text] [Related]
11. Viral delivery of P450 reductase recapitulates the ability of constitutive overexpression of reductase enzymes to potentiate the activity of mitomycin C in human breast cancer xenografts.
Cowen RL; Patterson AV; Telfer BA; Airley RE; Hobbs S; Phillips RM; Jaffar M; Stratford IJ; Williams KJ
Mol Cancer Ther; 2003 Sep; 2(9):901-9. PubMed ID: 14555709
[TBL] [Abstract][Full Text] [Related]
12. [DT-diaphorase].
Mikami K; Shirakusa T; Tsuruo T
Gan To Kagaku Ryoho; 1997 Sep; 24(11):1606-10. PubMed ID: 9309161
[TBL] [Abstract][Full Text] [Related]
13. Expression of DT-diaphorase and cytochrome P450 reductase correlates with mitomycin C activity in human bladder tumors.
Gan Y; Mo Y; Kalns JE; Lu J; Danenberg K; Danenberg P; Wientjes MG; Au JL
Clin Cancer Res; 2001 May; 7(5):1313-9. PubMed ID: 11350900
[TBL] [Abstract][Full Text] [Related]
14. Establishment by adriamycin exposure of multidrug-resistant rat ascites hepatoma AH130 cells showing low DT-diaphorase activity and high cross resistance to mitomycins.
Wakusawa S; Nakamura S; Miyamoto K
Jpn J Cancer Res; 1997 Jan; 88(1):88-96. PubMed ID: 9045901
[TBL] [Abstract][Full Text] [Related]
15. The role of NAD(P)H:quinone oxidoreductase in mitomycin C- and porfiromycin-resistant HCT 116 human colon-cancer cells.
Pan SS; Akman SA; Forrest GL; Hipsher C; Johnson R
Cancer Chemother Pharmacol; 1992; 31(1):23-31. PubMed ID: 1458556
[TBL] [Abstract][Full Text] [Related]
16. Factors influencing the induction of DT-diaphorase activity by 1,2-dithiole-3-thione in human tumor cell lines.
Begleiterabc A; Leith MK; Doherty GP; Digbya TJ; Pan S
Biochem Pharmacol; 2001 Apr; 61(8):955-64. PubMed ID: 11286987
[TBL] [Abstract][Full Text] [Related]
17. Unusually marked hypoxic sensitization to indoloquinone EO9 and mitomycin C in a human colon-tumour cell line that lacks DT-diaphorase activity.
Plumb JA; Workman P
Int J Cancer; 1994 Jan; 56(1):134-9. PubMed ID: 8262670
[TBL] [Abstract][Full Text] [Related]
18. Increased DT-diaphorase expression and cross-resistance to mitomycin C in a series of cisplatin-resistant human ovarian cancer cell lines.
O'Dwyer PJ; Perez RP; Yao KS; Godwin AK; Hamilton TC
Biochem Pharmacol; 1996 Jul; 52(1):21-7. PubMed ID: 8678904
[TBL] [Abstract][Full Text] [Related]
19. Role of NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase) in activation of mitomycin C under hypoxia.
Begleiter A; Robotham E; Leith MK
Mol Pharmacol; 1992 Apr; 41(4):677-82. PubMed ID: 1373799
[TBL] [Abstract][Full Text] [Related]
20. Involvement of activator protein-1 and nuclear factor-kappaB transcription factors in the control of the DT-diaphorase expression induced by mitomycin C treatment.
Yao KS; Hageboutros A; Ford P; O'Dwyer PJ
Mol Pharmacol; 1997 Mar; 51(3):422-30. PubMed ID: 9058597
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]